Mifamurtide Research Articles

Mifamurtide cost effective for osteosarcoma in the UK

Mifamurtide cost effective for osteosarcoma in the UK

Molecule of the month. Mifamurtide

Molecule of the month. Mifamurtide

Takeda Powers Ahead in Oncology

Takeda has agreed to acquire IDM Pharma for US$70 M. In March IDM received marketing approval of Mepact® (mifamurtide) for the treatment of non-metastatic osteosarcoma in patients and young adults.